EADV Congress 2026: 9 Late Breakers to Know

The 2026 European Academy of Dermatology and Venereology (EADV) Congress, held September 30 to October 3 in Vienna, Austria, delivered a broad dermatology program spanning psoriasis (PsO), atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus. The program featured multiple late-breaking abstract sessions, head-to-head trial data across the TYK2 inhibitor class, 2-year oral IL-23 receptor blocker data in both high-impact site and overall plaque psoriasis, and early phase results for novel targets in rare and underserved skin diseases. Here is a roundup of 9 headlines from EADV 2026.

1. EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

In the first head-to-head trial comparing two TYK2 inhibitors, zasocitinib achieved PASI 100 in a significantly higher proportion of patients with moderate to severe plaque psoriasis than deucravacitinib at week 16, while also outperforming on IGA 0/1 and PASI 75 endpoints. The data mark the first direct comparison within the TYK2 class and will be central to positioning discussions as the oral psoriasis landscape continues to expand.

2. ICONIC-TOTAL: Icotrokinra Sustains High-Impact Site Clearance at 2 Years

Two-year data from the ICONIC-TOTAL phase 3 trial showed oral icotrokinra maintained clearance at scalp, genital, hand/foot, and nail sites through week 112, with IGA 0/1 reaching 70% and complete genital clearance in 89% of patients at the 2-year mark. Nail psoriasis improvement continued to deepen through the full follow-up period, reaching 71% mNAPSI improvement at week 112, and adverse event rates did not rise with longer exposure.

3. Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD

Phase 2 data for tilrekimig (PF-07275315), an investigational trispecific antibody simultaneously targeting IL-4, IL-13, and TSLP, showed EASI-75 rates of 48% to 63% across all doses at week 16 in biologic-naive adults with moderate to severe atopic dermatitis, compared with 9% to 20% with placebo — the first public controlled efficacy data for any bispecific or trispecific antibody in the disease. HCPLive spoke with lead author Eric Simpson, MD, MCR, of Oregon Health & Science University in a video interview on the findings, the vIGA gap, and the absence of a conjunctivitis signal.

4. EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis

Telikibart (GR1802), a fully human anti-IL-4Rα monoclonal antibody with an engineered Fc region, met both coprimary endpoints in a phase 3 trial, with 69.6% of patients achieving EASI-75 at week 16 versus 22.5% with placebo and IGA 0/1 in 33.1% versus 6.6%. Responses deepened substantially during open-label maintenance, with EASI-75 exceeding 94% by week 52 in both the continuous-treatment and placebo-crossover groups.

5. Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD

Late-breaking phase 3 Tranquillo data showed ritlecitinib achieved F-VASI75 in 21.9% of patients versus 2.4% with placebo at week 52, with roughly 80% of ritlecitinib-treated patients remaining stable compared to approximately 60% on placebo — underscoring disease stabilization as a meaningful outcome in a condition where melanocyte recovery follows a fundamentally slower timeline than keratinocyte-driven diseases. HCPLive spoke with first author Iltefat Hamzavi, MD, in a video interview on why stabilization matters, what follicle density has to do with facial response patterns, and what the data suggest for combining systemic therapy with phototherapy.

6. Rezpegaldesleukin Hair Regrowth Climbs Through 1 Year in AA: David Rosmarin, MD

Fifty-two-week phase 2b REZOLVE-AA data showed rezpegaldesleukin, a Treg-inducing IL-2 receptor agonist, continued to increase hair regrowth after the treatment period ended — with SALT 20 or lower rates rising from 15.6% to 27.6% with the 24 µg/kg dose between weeks 36 and 52, including in patients who had not received the 16-week blinded extension. HCPLive spoke with presenter David Rosmarin, MD, of Indiana University School of Medicine, in a video interview on the deepening post-treatment response, how the mechanism differs from JAK inhibitors, and what phase 3 design decisions the data inform.

7. Brepocitinib Improves Cutaneous Sarcoidosis by Week 4: Aaron Mangold, MD

Phase 2 BEACON data showed brepocitinib 45 mg produced a mean 22.3-point reduction in CSAMI-A versus 0.7 points with placebo at week 16 (P < .0001), with all 13 patients in the highest-dose arm reporting improvement on the Patient Global Impression of Change — marking the first randomized, placebo-controlled efficacy data for any targeted therapy in cutaneous sarcoidosis. HCPLive spoke with presenter Aaron Mangold, MD, of Mayo Clinic Arizona, in a video interview about what rapid separation from placebo by week 4 suggests about the drug’s mechanism and what a phase 3 trial in this population would need to look like.

8. Daxdilimab Improves Discoid Lupus in Phase 2, With Victoria Werth, MD

Both doses of daxdilimab, an anti-ILT7 antibody targeting plasmacytoid dendritic cells, met the primary endpoint in a phase 2 trial in treatment-refractory discoid lupus, reducing CLASI-A scores by 6.0 and 5.7 points versus placebo at week 24, with CLASI-50 response rates above 60% for both doses compared to 23.7% with placebo. HCPLive spoke with lead investigator Victoria Werth, MD, of the University of Pennsylvania, in a video interview on how pDC-directed therapy could fit into the DLE treatment cascade and where other agents in the class are headed.

9. Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH

Late-breaking JAKPPPOT data showed upadacitinib met all prespecified feasibility thresholds in PPP — a condition with no licensed therapies in the UK or Europe — and produced a 77% mean reduction in PP-PASI over 8 weeks versus a 15% reduction in a matched historic placebo cohort, with PP-PASI75 achieved by 65% versus 3.2%. HCPLive spoke with trial investigator David Gleeson, BM BCh, of St John’s Institute of Dermatology and King’s College London, in a video interview on what the rebound after treatment withdrawal means for the disease biology, and why the next trial will need an active comparator rather than placebo.